New and recently funded Medical Startups
1
Country: USA | Funding: $50M
Avaneer Health creates health insurance platform that provides accurate coverage information by directly connecting payers and providers to accurately update coverage data before services are rendered and reimbursement claims are submitted. When updated or new coverage data is available, the solution automatically identifies missing, inconsistent, or incorrect coverage information. If needed, the information is instantly available in the electronic health record. The system uses blockchain and FHIR technologies to ensure secure data exchange between healthcare organizations.
Avaneer Health creates health insurance platform that provides accurate coverage information by directly connecting payers and providers to accurately update coverage data before services are rendered and reimbursement claims are submitted. When updated or new coverage data is available, the solution automatically identifies missing, inconsistent, or incorrect coverage information. If needed, the information is instantly available in the electronic health record. The system uses blockchain and FHIR technologies to ensure secure data exchange between healthcare organizations.
2
Country: Turkey
Salnus is a deep-tech medical AI startup building AI-powered preoperative surgical planning and clinical decision support for orthopedic surgery. Its software-only, implant-agnostic, browser-based platform runs an end-to-end DICOM pipeline covering knee osteoarthritis assessment, patient-specific surgical guides (PSI), and 3D preoperative surgical planning.
Salnus is a deep-tech medical AI startup building AI-powered preoperative surgical planning and clinical decision support for orthopedic surgery. Its software-only, implant-agnostic, browser-based platform runs an end-to-end DICOM pipeline covering knee osteoarthritis assessment, patient-specific surgical guides (PSI), and 3D preoperative surgical planning.
3
Country: USA | Funding: $1.7B
Intellia is a leading genome editing company specializing in the development of proprietary, potentially curative therapeutics using CRISPR/Cas9 technology. Intellia's co-founder Jennifer Daudna, along with Emmanuelle Charpentier, were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. The company's pipeline includes treatments for hereditary angioedema, transthyretin amyloidosis with polyneuropathy and cardiomyopathy, hemophilia, acute myeloid leukemia, and B-cell malignancies.
Intellia is a leading genome editing company specializing in the development of proprietary, potentially curative therapeutics using CRISPR/Cas9 technology. Intellia's co-founder Jennifer Daudna, along with Emmanuelle Charpentier, were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. The company's pipeline includes treatments for hereditary angioedema, transthyretin amyloidosis with polyneuropathy and cardiomyopathy, hemophilia, acute myeloid leukemia, and B-cell malignancies.
4
Country: France | Funding: €1,5M
deepColor specializes in developing and selling high-resolution 3D vascular imaging solutions using photoacoustic tomography.
deepColor specializes in developing and selling high-resolution 3D vascular imaging solutions using photoacoustic tomography.
5
Country: USA
Mendel Biosciences develops innovative technologies in longevity, regenerative medicine, and AI-powered healthcare to combat age-related diseases and extend healthy human lifespan
Mendel Biosciences develops innovative technologies in longevity, regenerative medicine, and AI-powered healthcare to combat age-related diseases and extend healthy human lifespan
6
Country: USA | Funding: $234.5M
City Therapeutics is focused on developing next-generation small interfering RNAs. Its lead candidate, CITY-FXI, is a potential best-in-class RNA interference-based therapeutic that targets a clotting factor. It can help prevent blood clots and serious conditions such as stroke, deep vein thrombosis (DVT), and myocardial infarction. By targeting a key protein called factor XI, CITY-FXI aims to protect patients from thrombosis while reducing the risk of bleeding. Another candidate, CITY-RBP4, is a promising RNA interference-based therapeutic for preventing vision loss in Stargardt disease.
City Therapeutics is focused on developing next-generation small interfering RNAs. Its lead candidate, CITY-FXI, is a potential best-in-class RNA interference-based therapeutic that targets a clotting factor. It can help prevent blood clots and serious conditions such as stroke, deep vein thrombosis (DVT), and myocardial infarction. By targeting a key protein called factor XI, CITY-FXI aims to protect patients from thrombosis while reducing the risk of bleeding. Another candidate, CITY-RBP4, is a promising RNA interference-based therapeutic for preventing vision loss in Stargardt disease.
7
Country: USA
AffinityCore is a trusted healthcare data analytics and revenue cycle management partner delivering advanced solutions in medical billing, healthcare data management, and operational intelligence.
AffinityCore is a trusted healthcare data analytics and revenue cycle management partner delivering advanced solutions in medical billing, healthcare data management, and operational intelligence.
8
Country: USA | Funding: $757.5M
Abridge develops AI-powered platform for recording and transcribing medical conversations and maintaining clinical documentation. Its enterprise-grade technology transforms patient-physician conversations into structured clinical notes in real time, with deep integration with electronic health records (EHRs). Using Linked Evidence and its proprietary, AI-verifiable model, the company compares AI-generated summaries with reference data, helping healthcare providers quickly trust and verify results and use the system to generate linked evidence. The system significantly simplifies the work of physicians, nurses, and revenue management teams system-wide.
Abridge develops AI-powered platform for recording and transcribing medical conversations and maintaining clinical documentation. Its enterprise-grade technology transforms patient-physician conversations into structured clinical notes in real time, with deep integration with electronic health records (EHRs). Using Linked Evidence and its proprietary, AI-verifiable model, the company compares AI-generated summaries with reference data, helping healthcare providers quickly trust and verify results and use the system to generate linked evidence. The system significantly simplifies the work of physicians, nurses, and revenue management teams system-wide.
9
Country: USA | Funding: $682.2M
NewLimit has created a screening platform to identify and test combinations of transcription factors - proteins that activate various genes - for liver cell rejuvenation. The company claims to have already identified at least ten such proteins in the form of mRNA within a lipid nanoparticle. Once delivered to the liver, this mRNA can be read by the cellular machinery and converted into functional proteins that help reset the organ's age. NewLimit's lead liver combination has proven effective in preclinical models, demonstrating the ability to enhance regenerative capacity in aged livers. The candidate is also able to increase alcohol tolerance in aged mice, making them more like young mice. NewLimit now plans to begin Phase I clinical trials.
NewLimit has created a screening platform to identify and test combinations of transcription factors - proteins that activate various genes - for liver cell rejuvenation. The company claims to have already identified at least ten such proteins in the form of mRNA within a lipid nanoparticle. Once delivered to the liver, this mRNA can be read by the cellular machinery and converted into functional proteins that help reset the organ's age. NewLimit's lead liver combination has proven effective in preclinical models, demonstrating the ability to enhance regenerative capacity in aged livers. The candidate is also able to increase alcohol tolerance in aged mice, making them more like young mice. NewLimit now plans to begin Phase I clinical trials.
10
Country: USA | Funding: $737.7M
Aura develops an AI privacy protection platform for families and collaborates with child psychologists to create online tools to protect children from cyberbullying. Parents can receive information on how to support healthy screen time and their children's overall well-being. Parents can also set screen time limits, block inappropriate websites, and receive real-time alerts about cyberbullying or predatory behavior in online games.
Aura develops an AI privacy protection platform for families and collaborates with child psychologists to create online tools to protect children from cyberbullying. Parents can receive information on how to support healthy screen time and their children's overall well-being. Parents can also set screen time limits, block inappropriate websites, and receive real-time alerts about cyberbullying or predatory behavior in online games.
